Fabian Stutz – CEO, Pharmabotix
Fabien Stutz, Co-Founder and CEO of Pharmabotix, leads a new wave of pharma-tech entrepreneurs combining engineering expertise with cutting-edge automation. He has helped grow the Swiss-based company into a globally…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Fabien Stutz, Co-Founder and CEO of Pharmabotix, leads a new wave of pharma-tech entrepreneurs combining engineering expertise with cutting-edge automation. He has helped grow the Swiss-based company into a globally…
From her beginnings as an operating room nurse to her current role as Head of Varian EMEA, Virve Sarja has shaped a career grounded in purpose and driven by innovation.…
Marie Leblanc brings a distinctive combination of scientific rigor and commercial acumen to her role as Executive Vice President of Life Sciences at Biosynth, drawing from an 18-year tenure at…
Stephan Fritschi, recently appointed CEO at CARBOGEN AMCIS, brings nearly three decades of institutional knowledge to his new position. With 29 years of experience within the organisation, he has witnessed…
Dr. Roch Ogier, CEO of OM Pharma, brings a strong background spanning clinical medicine, neuroscience research, and leadership roles at Sanofi-Aventis, Vifor Pharma, and Novartis. Over the past eighteen months,…
Ryad Dahmani is a leading figure in healthcare technology, driving innovation in pharmaceutical cold chain logistics and assistive healthcare solutions. As the founder of ColdChain Vision and Body Health Technologies,…
As kidney disease places mounting pressure on global healthcare systems, innovation in dialysis becomes all the more critical, especially for patients receiving therapy at home. Enter Vivatum: a Swiss-Swedish medtech…
FarmaMondo’s evolution over the past eight years is a compelling case study in what it takes to bring life-saving innovation to the world’s most overlooked patients, not through philanthropy but…
Jorge Santos da Silva is the CEO and Co-founder of MoonLake Immunotherapeutics, a Swiss biotech company known for its bold approach to drug development. With a background in neuroscience, a…
Dr. Olivier Michielin serves as Head of Oncology at Geneva University Hospital (HUG) and Head of the Division of Precision Oncology, whilst maintaining his professorship at the University of Geneva…
Pharmaceutical manufacturing is evolving into a strategic pillar of competitiveness, shaped by modular design, digital integration, and a growing focus on long-term efficiency. Bilfinger, through its Technology segment, is playing…
Urs Indermühle sees 2025 shaped by three big shifts and two urgent risks: R&D is now mostly sourced externally (just 35 percent developed in‑house), forcing pharma to master licensing and…
See our Cookie Privacy Policy Here
